Oct. 27 at 4:29 PM
$AUPH One more breadcrumb to spark discussion, anyone remember Gilead "sniffing" around Aurinia in late 2023? Interesting to note they have a deal with Galapagos.
https://pharmaphorum.com/news/galapagos-drops-plan-split-after-market-developments
The proposal also saw a 10-year,
$5.1 billion R&D alliance with Gilead Sciences significantly amended, with Galapagos regaining full rights to the pipeline of partnered projects. The company said it would stop working on small-molecule drugs, including TYK2 inhibitor GLPG3667, which is in phase 2 trials for systemic lupus erythematosus (SLE) and dermatomyositis, and seek development partners for these programmes.